Top

Published in:

17-05-2023 | Aplastic Anemia | Review Article

Comparison of haploidentical–allogeneic hematopoietic stem cell transplantation and intensive immunosuppressive therapy for patients with severe aplastic anemia with an absolute neutrophil count of zero: a retrospective study

Authors: Li-qiang Wu, Li-fang Huang, Hui Yang, Bao-dong Ye, Jian-ping Sheng, Qing-hong Yu, Yan Yang, Jin-song Jia, Dong-hua Zhang, Sheng-yun Lin, Guang-sheng He, Jian-yong Li

Published in: Annals of Hematology | Issue 8/2023

Abstract

A retrospective analysis was conducted based on the clinical data from 60 patients older than 16 years from January 2016 to January 2021. All the patients were newly diagnosed with severe aplastic anemia (SAA) with an absolute neutrophil count (ANC) of zero. We compared the hematological response and survival of haploidentical–allogeneic hematopoietic stem cell transplantation (HID-HSCT) (n = 25) and intensive immunosuppressive therapy (IST) (n = 35) treatments. At six months, the overall response rate and complete response were significantly higher in the HID-HSCT group than those in the IST group (84.0% vs. 40.0%, P = 0.001; 80.0% vs. 17.1%, P = 0.001). With a median follow-up of 18.5 months (4.3~30.8 months), patients in the HID-HSCT group had longer overall survival and event-free survival (80.0% vs. 47.9%, P = 0.0419; 79.2% vs. 33.5%, P = 0.0048). These data suggested that HID-HSCT might be an effective alternative treatment option for adult patients with SAA with an ANC of zero, which requires further validation in an additional prospective study.

Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A et al (2016) Guidelines for the diagnosis and management of adult aplastic anemia. Br J Haematol 172(2):187–207. e-pub ahead of print 2015/11/17. https://doi.org/10.1111/bjh.13853CrossRefPubMed

Young NS (2018) Aplastic anemia. N Engl J Med 379(17):1643–1656. e-pub ahead of print 2018/10/26. https://doi.org/10.1056/NEJMra1413485CrossRefPubMedPubMedCentral

Bacigalupo A (2017) How I treat acquired aplastic anemia. Blood 129(11):1428–1436. e-pub ahead of print 2017/01/18. https://doi.org/10.1182/blood-2016-08-693481CrossRefPubMed

Kojima S, Hibi S, Kosaka Y, Yamamoto M, Tsuchida M, Mugishima H et al (2000) Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood 96(6):2049–2054 e-pub ahead of print 2000/09/09CrossRefPubMed

Rosenfeld S, Follmann D, Nunez O, Young NS (2003) Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA 289(9):1130–1135. e-pub ahead of print 2003/03/08. https://doi.org/10.1001/jama.289.9.1130CrossRefPubMed

Yoshizato T, Dumitriu B, Hosokawa K, Makishima H, Yoshida K, Townsley D et al (2015) Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. N Engl J Med 373(1):35–47. e-pub ahead of print 2015/07/02. https://doi.org/10.1056/NEJMoa1414799CrossRefPubMedPubMedCentral

Kulasekararaj AG, Jiang J, Smith AE, Mohamedali AM, Mian S, Gandhi S et al (2014) Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome. Blood 124(17):2698–2704. e-pub ahead of print 2014/08/21. https://doi.org/10.1182/blood-2014-05-574889CrossRefPubMedPubMedCentral

Bejanyan N, Kim S, Hebert KM, Kekre N, Abdel-Azim H, Ahmed I et al (2019) Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Blood Adv 3(20):3123–3131. e-pub ahead of print 2019/10/28. https://doi.org/10.1182/bloodadvances.2019000722CrossRefPubMedPubMedCentral

Yang D, Yang J, Hu X, Chen J, Gao L, Cheng H et al (2019) Aplastic anemia preconditioned with fludarabine, cyclophosphamide, and anti-thymocyte globulin. Ann Transplant 24:461–471. e-pub ahead of print 2019/08/10. https://doi.org/10.12659/AOT.915696CrossRefPubMedPubMedCentral

10.

Kekre N, Zhang Y, Zhang MJ, Carreras J, Ahmed P, Anderlini P et al (2017) Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia. Haematologica 102(7):1291–1298. e-pub ahead of print 2017/03/28. https://doi.org/10.3324/haematol.2017.164459CrossRefPubMedPubMedCentral

11.

Zhang Y, Wu L, Mo W, Zhou M, Li Y, Chen X et al (2019) Comparable outcomes of first-line hematopoietic stem cell transplantation from unrelated and matched sibling donors in adult patients with aplastic anemia: a retrospective single-center study. Biol Blood Marrow Transplant 25(8):1567–1575CrossRefPubMed

12.

Liu L, Zhang Y, Jiao W, Zhou H, Wang Q, Jin S et al (2020) Comparison of efficacy and health-related quality of life of first-line haploidentical hematopoietic stem cell transplantation with unrelated cord blood infusion and first-line immunosuppressive therapy for acquired severe aplastic anemia. Leukemia 34(12):3359–3369CrossRefPubMed

13.

Esteves I, Bonfim C, Pasquini R, Funke V, Pereira NF, Rocha V et al (2015) Haploidentical BMT and post-transplant Cy for severe aplastic anemia: a multicenter retrospective study. Bone Marrow Transplant 50(5):685–689CrossRefPubMed

14.

Xu LP, Wang SQ, Wu DP, Wang JM, Gao SJ, Jiang M et al (2016) Haplo-identical transplantation for acquired severe aplastic anemia in a multicentre prospective study. Br J Haematol 175(2):265–274. e-pub ahead of print 2016/06/29. https://doi.org/10.1111/bjh.14225CrossRefPubMed

15.

Xu LP, Jin S, Wang SQ, Xia LH, Bai H, Gao SJ et al (2017) Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant. J Hematol Oncol 10(1):25. e-pub ahead of print 2017/01/22. https://doi.org/10.1186/s13045-017-0398-yCrossRefPubMedPubMedCentral

16.

Bacigalupo A, Hows J, Gluckman E, Nissen C, Marsh J, Van Lint MT et al (1988) Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anemia (SAA): a report of the EBMT SAA working party. Br J Haematol 70(2):177–182. e-pub ahead of print 1988/10/01. https://doi.org/10.1111/j.1365-2141.1988.tb02460.xCrossRefPubMed

17.

Xu LP, Wang SQ, Ma YR, Gao SJ, Cheng YF, Zhang YY et al (2019) Who is the best haploidentical donor for acquired severe aplastic anemia? Experience from a multicenter study. J Hematol Oncol 12(1):87. e-pub ahead of print 2019/09/02. https://doi.org/10.1186/s13045-019-0775-9CrossRefPubMedPubMedCentral

18.

Yagasaki H, Shichino H, Ohara A, Kobayashi R, Yabe H, Ohga S et al (2014) Immunosuppressive therapy with horse anti-thymocyte globulin and cyclosporine as a treatment for fulminant aplastic anemia in children. Ann Hematol 93(5):747–752. e-pub ahead of print 2013/12/18. https://doi.org/10.1007/s00277-013-1984-xCrossRefPubMed

19.

Liu J, Lu XY, Cheng L, Yang Y, Lin SY, Yin H et al (2019) Clinical outcomes of immunosuppressive therapy for severe aplastic anemia patients with an absolute neutrophil count of zero. Hematology 24(1):492–497. e-pub ahead of print 2019/06/22. https://doi.org/10.1080/16078454.2019.1631424CrossRefPubMed

20.

Peffault de Latour R, Tabrizi R, Marcais A, Leblanc T, Lamy T, Mohty M et al (2018) Nationwide survey on the use of horse antithymocyte globulins (ATGAM) in patients with acquired aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia. Am J Hematol 93(5):635–642. e-pub ahead of print 2018/01/30. https://doi.org/10.1002/ajh.25050CrossRefPubMed

21.

ElGohary G, El Fakih R, de Latour R, Risitano A, Marsh J, Schrezenmeier H et al (2020) Haploidentical hematopoietic stem cell transplantation in aplastic anemia: a systematic review and meta-analysis of clinical outcome on behalf of the severe aplastic anemia working party of the European group for blood and marrow transplantation (SAAWP of EBMT). Bone Marrow Transplant 55(10):1906–1917. e-pub ahead of print 2020/04/30. https://doi.org/10.1038/s41409-020-0897-2CrossRefPubMed

22.

Xu ZL, Huang XJ (2021) Haploidentical stem cell transplantation for aplastic anemia: the current advances and future challenges. Bone Marrow Transplant 56(4):779–785. e-pub ahead of print 2020/12/17. https://doi.org/10.1038/s41409-020-01169-7CrossRefPubMed

23.

Iftikhar R, Chaudhry QUN, Anwer F, Neupane K, Rafae A, Mahmood SK et al (2021) Allogeneic hematopoietic stem cell transplantation in aplastic anemia: current indications and transplant strategies. Blood Rev 47:100772. e-pub ahead of print 2020/11/15. https://doi.org/10.1016/j.blre.2020.100772CrossRefPubMed

24.

Kahl C, Leisenring W, Deeg HJ, Chauncey TR, Flowers ME, Martin PJ et al (2005) Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up. Br J Haematol 130(5):747–751. e-pub ahead of print 2005/08/24. https://doi.org/10.1111/j.1365-2141.2005.05667.xCrossRefPubMed

25.

Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X et al (2015) Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood 125(25):3956–3962. e-pub ahead of print 2015/05/06. https://doi.org/10.1182/blood-2015-02-627786CrossRefPubMed

26.

Im HJ, Koh KN, Seo JJ (2015) Haploidentical hematopoietic stem cell transplantation in children and adolescents with acquired severe aplastic anemia. Korean J Pediatr 58(6):199–205. e-pub ahead of print 2015/07/28. https://doi.org/10.3345/kjp.2015.58.6.199CrossRefPubMedPubMedCentral

27.

Viollier R, Passweg J, Gregor M, Favre G, Kuhne T, Nissen C et al (2005) Quality-adjusted survival analysis shows differences in outcome after immunosuppression or bone marrow transplantation in aplastic anemia. Ann Hematol 84(1):47–55. e-pub ahead of print 2004/09/02. https://doi.org/10.1007/s00277-004-0930-3CrossRefPubMed

Title: Comparison of haploidentical–allogeneic hematopoietic stem cell transplantation and intensive immunosuppressive therapy for patients with severe aplastic anemia with an absolute neutrophil count of zero: a retrospective study
Authors: Li-qiang Wu
Li-fang Huang
Hui Yang
Bao-dong Ye
Jian-ping Sheng
Qing-hong Yu
Yan Yang
Jin-song Jia
Dong-hua Zhang
Sheng-yun Lin
Guang-sheng He
Jian-yong Li
Publication date: 17-05-2023
Publisher: Springer Berlin Heidelberg
Keywords: Aplastic Anemia
Stem Cell Transplantation
Stem Cell Transplantion
Stem Cell Transplantation
Published in: Annals of Hematology / Issue 8/2023
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-023-05256-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2023

Establishment of the Abu Dhabi Emirate Thalassemia Longitudinal Cohort (AD-TLC): leveraging the power of observation

Global profile of anemia during pregnancy versus country income overview: 19 years estimative (2000–2019)

Correction to: Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States

Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma—a real-world multicenter retrospective cohort study

Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis

Impacts of early therapy response, interval to therapy interruption, and cumulative therapy interruption duration on outcome of ibrutinib therapy in relapsed/refractory chronic lymphocytic leukemia

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials